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Objectives: Management of diabetes is a balancing act of preventing a state of hyperglycaemia while avoiding episodes of
hypoglycaemia. Limited information is currently available on the incidence of hypoglycaemia in South African people
diagnosed with diabetes. Data regarding the management of diabetes and incidence of hypoglycaemia in the South African
population was collected as part of Wave 7 of the International Diabetes Management Practices Study (IDMPS).
Design and methods: During this observational study the first 10 adult individuals with type 2 diabetes and the first five adult
individuals with type 1 diabetes presenting to a study site during the two-week study period were enrolled.
Setting: Patients were enrolled from the private healthcare sector in South Africa only.
Subjects: A total of 445 individuals (49 diagnosed with T1D, 396 diagnosed with T2D) were included.
Outcome measures: Glycated haemoglobin and hypoglycaemia data were recorded for each patient.
Results: Of the patients who reported experiencing hypoglycaemia, 48.6% (17/35) among T1D individuals and 67.8% (40/71)
among T2D individuals experienced hypoglycaemia over a four-week period. Furthermore, in patients who discontinued
insulin treatment (n = 11), fear of hypoglycaemia was reported to influence adherence to insulin treatment by 27.3% in T1D
and T2D individuals. Of the 148 patients not achieving their HbA1c target, 23.0% reported fear of hypoglycaemia as a reason.
Conclusions: This report demonstrates the need to address hypoglycaemia and fear of hypoglycaemia in the South African
diabetes population.
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Introduction
Diabetes is characterised by hyperglycaemia due to deficient
insulin secretion, as in Type 1 diabetes (T1D), insufficient
insulin secretion and/or insulin resistance, as in Type 2 diabetes
(T2D).1 Exogenous insulin is regarded as the treatment for
patients with T1D.1,2 While a range of oral anti-hyperglycaemic
treatments is available for the treatment of T2D, the progressive
nature of the disease may ultimately require the use of exogen-
ous insulin to reach and maintain glycaemic goals.1,3,4 Exogen-
ous insulin5 and certain oral anti-hyperglycaemic agents, such
as sulfonylureas,6 are associated with an increased risk of hypo-
glycaemia. Long-term management of diabetes is thus a balan-
cing act between achieving glycaemic targets and concurrently
avoiding episodes of hypoglycaemia.
Clinically relevant hypoglycaemia is defined as blood glucose
levels < 3.0 mmol/l, while blood glucose levels < 3.9 mmol/l
should be regarded as a cautionary signal.1,7 Such low levels
of blood glucose have been associated with cardiac arrhythmias
in patients diagnosed with T2D,8,9 increased risk for myocardial
infarction,10 elevated levels of inflammatory markers,10 coma,11
neuronal damage12 and increased microvascular events.13
Several studies have also reported increased mortality rates
associated with severe hypoglycaemia, including the
ADVANCE13, ACCORD14 and NICE-Sugar studies.15
As there is currently not a national diabetes registry in
South Africa, limited data are available on the burden of
hypoglycaemia in patients diagnosed with diabetes in South
Africa. The International Diabetes Management Practices Study
(IDMPS) was an international registry of patients diagnosed
with diabetes conducted in 24 countries. This report is based
on the data recorded for hypoglycaemia for patients diagnosed
with T1D and T2D participating in the South African cohort in
2016 (Wave 7).
The International Diabetes Management Practices Study (IDMPS)
is an international, multicentre, observational registry. The
primary objective of the study was to evaluate the management
of patients with T2D in current medical practice. The secondary
objectives of the study were to assess the management of
patients diagnosed with T1D in current medical practice, and
to investigate the predictive factors for reaching target HbA1c
in patients with diabetes.
Methods and materials
Site selection
A total of 38 study sites participated in the study in South Africa.
Participating physicians were requested to include the first 10
adult T2D patients and the first five adult T1D patients present-
ing to their practice during the two-week study period. This
recruitment strategy was aimed at enrolling a random patient
sample in the survey, and therefore does not reflect the manage-
ment of diabetes at a particular site. To ensure that the partici-
pating physicians were representative of physicians managing
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diabetes in South Africa, a stratified sample was randomly
selected. The stratification was based on the speciality of the
physician (endocrinologist, specialist physician, diabetologists
or general practitioners). The majority of patients included in
the study accessed health care in the private healthcare setting.
Patient selection
Adult patients diagnosed with type 1 or type 2 diabetes mellitus,
who consulted the participating physicians during the two-week
recruitment period, were invited to participate and provide
informed consent. Exclusion criteria included concomitant par-
ticipation in a clinical trial and/or current temporary insulin
therapy (gestational diabetes, pancreatic cancer, surgery).
Information was collected using questionnaires completed by
physician and patient.
Sample size determination
The sample size was determined per country, based on the
primary objective and the expected precision. In addition, it
was assumed that insulin is the least prescribed therapy in
terms of proportions and thus the sample size was determined
to establish the frequency of insulin treatment.
The sample size was estimated to give an estimation of pro-
portions with an absolute precision of 20% and a confidence
interval of 95%. The following calculations were used:
n = p(1− p)× (1.96/e)2
Where: n = the per country sample size; p = the estimated pro-
portion of T2D patients treated with insulin (based on local feed-
back, for RSA insulinisation was estimated to be 20%); e = the
absolute precision (20%) × p = the relative precision.
Given this information, a computation table was developed,
taking into account the proportion of insulin treatment. For
example, if in a given country, 10% of patients receive insulin
(p) with an absolute precision of 20%, the sample size
(number of T2D patients to be recruited) would be 864 patients
in this country for each cross-sectional survey. Based on these
calculations, 447 patients formed the pre-specified sample for
South Africa.
Statistical methods
Analyses performed on the database were mainly descriptive.
Qualitative data were summarised using number of non-
missing data, number of missing data, counts and percentages
(two-sided confidence interval (CI) 95% of proportion if perti-
nent), and quantitative data were summarised using qualitative
descriptive statistics (number of non-missing data, number of
missing data, mean, standard deviations, median, first and
third quartiles, minimum and maximum). Statistical analyses
were conducted with SAS Software version 9.2 (SAS Institute,
Cary, NC, USA). AdClin Software version 3.1.4 (AdClin, Paris,
France, www.adclin.com) was used to format tables and listings.
Ethics
The survey was conducted according to the principles estab-
lished in the 18th World Medical Assembly (Helsinki, 1964) and
all subsequent amendments, and in accordance with the guide-
lines for Good Clinical Practice. Ethical approval for the study
was obtained from Pharma-Ethics. Written informed consent
was obtained from all the participating patients prior to
inclusion in the study.
Results
Baseline characteristics
A total of 445 patients (49 diagnosed with T1D 396 diagnosed
with T2D) were included in the South African cohort of the
IDMPS Wave 7 study. These patients were enrolled by a total
of 38 doctors, which included nine specialists (endocrinologists
or diabetologists) and 29 non-specialists (general practitioners).
Baseline characteristics for the South African cohort are dis-
played in Table 1.
Patients were obese (average BMI > 31 kg/m2), had longstand-
ing diabetes (average disease duration 12.13 years) and were
poorly controlled with an average HbA1c of 8.0% recorded for
the entire study population (see Table 1). Approximately 83.8%
of patients had private health insurance and an estimated
53.5% of patients reported being employed. Patients reported
taking up to 7.3 days of sick leave in the three months prior to
participation in the study.
Therapeutic regimens used
In this study, a total of 49 (100%) patients diagnosed with T1D
and 180 (45.4%) patients diagnosed with T2D reported receiving
insulin treatment. The majority of T1D patients (83.7%) reported
the use of basal and prandial insulin, while 10.2% were treated
with premix insulin. Of the 180 T2D patients on treatment
with insulin, 100 (55.5%) indicated treatment with basal








Age (mean ± SD) 42.6 ± 14.7 58.4 ± 11.2 56.7 ± 12.6
Gender (% male) 40.8 54.0 52.6
BMI (kg/m2± SD) 25.1 ± 4.8 31.9 ± 6.5 31.2 ± 6.7
BMI > 30 kg/m2, n (%) 1 (2) 79 (19.9) 80 (18.0)
HbA1c (% ± SD) 8.6 ± 1.8 7.9 ± 1.8 8.0 ± 1.8
Duration of diabetes (years) 19.0 ± 13.7 11.3 ± 8.1 12.1 ± 9.2
Ethnicity: Caucasian/Black/Other (%) 71.4/6.1/22.5 32.8/24.5/42.7 37.1/22.5/40.5
Patients with private health insurance, n (%) 44 (89.8) 329 (83.1) 373 (83.8)
Patients with tertiary education, n (%) 32 (65.3) 162 (40.9) 194 (43.6)
Employed (full time or part time, %) 75.5 50.8 53.5
Sick leave taken in the preceding 3 months (days, mean ± SD) 3.0 ± 3.0 8.5 ± 14.1 7.3 ± 12.7
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insulin, 53 (29.4%) reported use of a prandial insulin and 74
(41.1%) reported treatment with premix insulin.
The basal insulins used included long-acting insulin analogues
(79.0% of patients), intermediate human insulin (15.9% of
patients) or biosimilar insulin (5.1% of patients). Prandial insulins
used included short-acting insulin analogues (78.5% of patients),
rapid-acting human insulins (19.4% of patients) and biosimilar
insulin (2.2% of patients).
Treatment with oral agents was reported in 90.5% of the
patients enrolled in the study. A total of 9 (18.3%) T1D patients
reported the use of OGLD, which consisted of biguanides (8
patients) and the combination of biguanides and sulfonylureas
(1 patient). Of the T2D patients on treatment with oral anti-
hyperglycaemic agents, a total of 344 (93.5%) patients were
on treatment with biguanides, 139 (37.8%) patients reported
the use of sulfonylureas and 21 (5.7%) patients received other
OGLD treatment.
Self-adjustment of insulin doses were reported by 85.7% of T1D
patients and 51.1% of T2D patients currently on treatment with
insulin.
All T1D patients and 97.2% of T2D patients reported self-moni-
toring of blood glucose levels. Data indicated similar rates of
self-monitoring of blood glucose levels in patients diagnosed
with T2D for patients on treatment with oral glucose lowering
drugs (96%), insulin (95.2%) and a combination of oral glucose
lowering drugs and insulin (98.7%). Patients were asked to clas-
sify their habitual self-monitoring of blood glucose levels in
different categories: daily monitoring (reported by 54.6% of
patients), occasional monitoring (reported by 32.5% of patients),
seldom monitoring (reported by 8.9% of patients), only very
occasionally (reported by 3.8% of patients) and unknown
(reported by 0.3% of patients) (Supplementary Table 1).
Results indicate that 18.9% of patients reported monitoring of
blood glucose levels at all meals, 54.5% of patients reported
testing at some meals, 27% of patients reported monitoring at
bedtime and for 9% of patients the time of monitoring was
not recorded. Mean number of tests per day was reported as
1.7 (see Supplementary Table 1). Data correlating frequency or
timing of monitoring with episodes of hypoglycaemia was not
recorded.
Of 229 patients on insulin, 148 (66.7%) failed to reach the HbA1c
target set by their treating physician. Of this group, 43.9% indi-
cated that insufficient titration of insulin is the reason for failure.
Fear of hypoglycaemia was reported as the main obstacle to
reaching HbA1c target by approximately 23% of patients. This
was most evident in patients diagnosed with T1D (Table 2).
Furthermore, 4.8% (n = 11) of the 229 insulin-treated patients in
this study had previously discontinued insulin treatment. Fear of
hypoglycaemia was one of the main reasons for non-adherence
reported by this group (27.3%) (Table 3). Of the 148 patients not
achieving their HbA1c target, 23.0% reported fear of hypogly-
caemia as a reason.
One T1D patient and 73 T2D patients reported treatment with
beta blockers. Of the T2D patients on treatment with beta block-
ers, 36 were also on treatment with insulin.
Hypoglycaemia
During the IDMPS study, data were collected on the incidence of
symptomatic hypoglycaemia and severe hypoglycaemia,
defined as an episode requiring assistance from a third party
as per ADA recommendations.16 Confirmation of blood
glucose levels was not required to validate reported events.
Of the T1D patients included in this study, only 38 (77.6%)
patients reportedly experienced symptomatic episodes of hypo-
glycaemia in the preceding 3 months (Table 4). A total of 35 of
these patients provided information on the frequency of hypo-
glycaemia and 17 (48.6%) patients reportedly experienced at
least one episode of hypoglycaemia per month.
A total of 71 T2D patients on treatment with OGLD or the com-
bination of OGLD and insulin reported experiencing sympto-
matic episodes of hypoglycaemia in the preceding 3 months.
Of these, 59 provided information on the frequency of hypogly-
caemia episodes and 40 (67.8%) of these patients reportedly
experienced an episode of hypoglycaemia on a monthly basis
(Table 4).
Severe hypoglycaemia in the 12 months prior to the study was
reported by 22.4% and 5.4% of patients diagnosed with T1D
and T2D, respectively. Severe hypoglycaemia was reported by
patients on treatment with OGLD only, the combination of
OGLD and insulin or insulin only.
The number of emergency room visits due to hypoglycaemia
reported in this study ‘for a 12 month period’ was low, with a
mean of 0.3 for T1D patients and 0.01 for T2D patients. The
number of patients seeking medical attention at an emergency
room and the frequency thereof were not recorded.
The majority of T2D patients who experienced hypoglycaemia,
either symptomatic or severe, were on treatment with insulin,
either alone or in combination with oral anti-hyperglycaemic









Lack of titration of insulin 38.2% 45.6% 43.9%
Fear of hypoglycaemia 29.4% 21.1% 23.0%
Lack of experience in self-
management of insulin dose
17.6% 32.5% 29.1%




*Based on the cohort who did not reach glycaemic target set by the treating phys-
ician as indicated by HbA1c.





Fear of hypoglycaemia 3 (27.3%)
Lack of efficacy 2 (18.2%)
Occurrence of side effects 2 (18.2%)
Impact on social life 2 (18.2%)
Lack of support 2 (18.2%)
*Of the total cohort, 11 patients reported discontinuing insulin treatment. This
number includes T1D and T2D patients.
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agents (Table 4). Some 46.4% of patients diagnosed with T2D
were treated with sulfonylureas, whether in combination with
other oral anti-hyperglycaemic agents or as monotherapy.
Approximately 26.1% of patients diagnosed with T2D reported
treatment with a combination of sulfonylureas and insulin.
A number of factors contributing to severe hypoglycaemia were
proposed by participants. These included inappropriate man-
agement of insulin (59.4% of T1D and T2D patients), emotional
distress (40.6% of T1D and T2D patients) and inappropriate
dosage of insulin (37.5% of T1D and T2D patients) (Supplemen-
tary Table 2). Two patients from the South African cohort listed
lack of self-testing of blood glucose levels as a factor contribut-
ing to severe hypoglycaemia.
Discussion
Hypo- and hyperglycaemia have been associated with adverse
health outcomes.17 The aim of treatment in patients diagnosed
with diabetes is the correction of hyperglycaemia, while avoid-
ing episodes of hypoglycaemia. Data collected for the South
African cohort of the International Diabetes Management Prac-
tices Study, with a particular focus on hypoglycaemia, is pre-
sented in this report.
The incidence of hypoglycaemia over a four-week period was
reported as 48.6% (17/35) in T1D individuals and 67.8% (40/71)
in T2D individuals. Furthermore, in patients who discontinued
insulin treatment, fear of hypoglycaemia was reported to influ-
ence adherence to insulin treatment by 27.3% in T1D and T2D
individuals. Of the 148 patients not achieving their HbA1c
target, 23.0% reported fear of hypoglycaemia as a reason.
Accurate reporting of episodes of hypoglycaemia can prove
challenging due to hypoglycaemia unawareness. Indeed, a
study utilising continuous glucose monitoring reported that
patients diagnosed with T2D are aware of only 39% of diurnal
and 11% of nocturnal episodes of hypoglycaemia.9 In the
current study blood glucose levels were not reported, and it is
therefore possible that the incidence of hypoglycaemia may
have been underreported as asymptomatic episodes may not
have been reported. In contrast, a patient’s perceived
symptomatic hypoglycaemia does not automatically equate to
clinically relevant low serum glucose levels. As confirmation of
blood glucose levels was not required to validate patient
reports, over-reporting of hypoglycaemia may have occurred,
which limits accurate reflection of true incidence.
It should be considered that various additional factors may influ-
ence reporting of hypoglycaemia episodes. The presence of sig-
nificant diabetes-related complications, including diabetic
nephropathy or autonomic neuropathy, could contribute to
the increased incidence of hypoglycaemia. Furthermore, the
use of other therapeutic agents, including beta blockers for
the management of hypertension, especially in the T2D popu-
lation, could mask adrenergic response to hypoglycaemia,
which in turn could contribute to under-reporting of hypogly-
caemia. Several patients enrolled in the study were on treatment
with beta blockers in addition to antihyperglycemic agents.
Unfortunately data were not collected to indicate the incidence
of hypoglycaemia in these patients.
Data collected for the South African cohort of the IDMPS Wave 7
study indicates that hypoglycaemia, and fear of hypoglycaemia,
may still be an obstacle to reaching glycaemic targets (Tables 2
and 3). These data reflect perceived patient barriers to achieving
glycaemic targets and confirm the results of a large multina-
tional online survey, the Global Attitude of Patients and Phys-
icians 2 (GAPP-2) study.18 The GAPP-2 study reported that fear
of hypoglycaemia was one of the most common factors in
patients’ intentional basal insulin dosing irregularities.18
However, it has also been demonstrated that fear of hypoglycae-
mia is a consideration for physicians when prescribing insulin
treatment. A total 75.5% of physicians participating in the
GAPP-1 study reported that insulin treatment would be pre-
scribed more aggressively if the fear of hypoglycaemia could
be eliminated.19 Similar results describing the fear of hypogly-
caemia as a barrier for patient and physicians alike were
reported by Ross et al. in an extensive literature review.20
Fear of hypoglycaemia may also affect the patient’s willingness
to adhere to prescribed treatment, compromising achievement
of glycaemic targets. In a recent retrospective study using elec-
tronic medical records for patients diagnosed with T2D, Dalal













Patients with symptomatic hypoglycaemia in
the last 3 months,
n (%)
38 (77.6) 0 (0) 15 (7.1) 56 (31) 109 (24.6)
Patients with severe hypoglycaemia*** in the
last 12 months,
n (%)
11 (22.4) 0 (0) 3 (1.4) 18 (0.1) 32 (7.3)
Frequency of hypoglycaemia episodes, n (%)










At least once per month, n (%) 17 (48.6) 7 (77.8) 33 (66.0) 57 (60.6)
At least once per week, n (%) 18 (51.4) 2 (22.2) 17 (34.0) 37 (39.4)
*Includes treatment with diet and exercise only and ‘other’, non-pharmacological treatment.
**Includes patients on treatment with combination of OGLD and insulin (n = 159), as well as patients on treatment with insulin only (n = 21).
***Requiring assistance.
OGLD: oral glucose lowering drugs.
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and colleagues investigated patients’ persistence on insulin
treatment after one or more episode of hypoglycaemia.21 The
study demonstrated that 68% of patients who had experienced
hypoglycaemia discontinued insulin treatment in the first 12
months. The incidence of hypoglycaemia was reported as
10.5% in the first six months after initiation of basal insulin
treatment.21
It is important that healthcare professionals identify and
acknowledge the fear of hypoglycaemia. The requisite facility,
through routine outpatient consultation, should be provided
to discuss the fear and develop strategies to assist patients in
overcoming this barrier. A helpful tool designed for this
purpose is the Hypoglycaemia Fear Survey, which, if
implemented in appropriate cases, may prove invaluable in edu-
cating patients and modifying entrenched patient and physician
behaviours.22
Data indicated that 22.4% of patients diagnosed with type 1 dia-
betes and 5.4% of patients diagnosed with T2D experienced at
least one episode of severe hypoglycaemia in the year preced-
ing the study (Table 4). A higher incidence of severe hypoglycae-
mia was reported in patients diagnosed with T2D on treatment
with insulin (14.3%) or the combination of insulin and oral anti-
hyperglycaemic agents (9.6%) than for patients on treatment
with oral anti-hyperglycaemic agents alone (1.4%) (see Table
4). These rates are similar to those reported by Dalal and col-
leagues.21 Another non-interventional study, the Hypoglycaemia
Assessment Tool (HAT), reported that 14.4% of participants diag-
nosed with T1D and 8.9% of participants diagnosed with T2D
reported an episode of severe hypoglycaemia.23 Only patients
on treatment with insulin were included in the HAT study; no
mention was made of the use of oral anti-hyperglycaemic
agents.23
When compared with the results of the HAT study, patients diag-
nosed with T1D in the South African cohort of the IDMPS Wave 7
study seem to experience episodes of hypoglycaemia more fre-
quently. The incidence of severe hypoglycaemia in the T2D
population treated with insulin was reported as > 10% in both
studies. It should be considered that the IDMPS Wave 7 study
recorded episodes of severe hypoglycaemia over a 12-month
period, while the HAT study recorded episodes of severe hypo-
glycaemia over four weeks only. It is not surprising that patients
diagnosed with T1Dmay be at higher risk for severe hypoglycae-
mia than their T2D counterparts.
The cost of hypoglycaemia, and in particular severe hypoglycae-
mia, extends beyond pure economic cost, as hypoglycaemia
affects productivity and quality of life, and remains an obstacle
to reach glycaemic targets. The cost of one event of severe
hypoglycaemia is estimated to range from US$ 1 746 to US$ 3
525.24 Even though differences in healthcare systems do not
allow for direct translation of this cost, it is alarming to note
that hypoglycaemia-related hospitalisation costs increase sub-
stantially when the number of hypoglycaemia events exceeds
six per year.25 Results from the current study (see Table 4) and
the HAT study23 reported hospitalisation due to hypoglycaemia
in both the South African and international cohorts. It must be
considered that therapeutic regimens are often not included
in these health economic reports.
It is well known that some anti-hyperglycaemic treatments,
especially sulfonylureas5 and insulin,6 are associated with
increased risk of hypoglycaemia. In addition, co-morbidities
including renal dysfunction increase the risk of hypoglycae-
mia.26 Considering that insulin is the cornerstone of treatment
for patients diagnosed with T1D,1 the increased incidence of
hypoglycaemia in this population is not completely surprising.
Inappropriate management of insulin, inappropriate dosing of
insulin and inappropriate timing of insulin were mentioned
among the major factors contributing to severe hypoglycaemia
in the present study (see Table 4). To address these factors con-
tributing to severe hypoglycaemia a number of tactics should be
considered, including selecting treatments with low risk of hypo-
glycaemia, a multidisciplinary approach to patient education to
ensure appropriate patient-level management of insulin therapy
and caution in insulin-treated patients with renal failure or in
patients with blunting of awareness of hypoglycaemia.
In order to reduce treatment-related hypoglycaemia, a number
of novel treatments have been developed with lower risk for
hypoglycaemia, such as glucagon-like peptide receptor-1 ago-
nists (GLP-1RAs) and sodium-glucose co-transporter-2 inhibitors.
Clinical study programmes for the GLP-1RAs liraglutide and lixi-
senatide have demonstrated minimal risk for hypoglycaemia in
heterogeneous populations of patients with diabetes.27–29 Fur-
thermore clinical studies on longer acting basal insulins, includ-
ing insulin degludec and insulin glargine U300, have
demonstrated a reduced risk of hypoglycaemia in extensive
phase three clinical trials in comparison with other available
insulin analogues.30–32 Some of these treatments are costly
and the benefit to the patient should be weighed against this
potential increased treatment cost.
A recent study of insulin-naive patients diagnosed with T2D has
demonstrated that patients who experienced hypoglycaemia
during the first three months of initiation of basal insulin
therapy were at higher risk of experiencing recurring hypogly-
caemia.33 As hypoglycaemia may adversely affect the achieve-
ment of glycaemic goals, it is vital to ensure that patients
diagnosed with diabetes and treated with insulin receive appro-
priate education on the treatment as well as the management of
hypoglycaemia.
Recently, reports have alluded to an association between hypo-
glycaemia and adverse cardiovascular events.34 However, the
potential correlation of severe hypoglycaemic events and
macrovascular complications, including acute coronary syn-
dromes, is clearly impossible to gauge given the limited access
to all clinical data. Thus, it is difficult to extrapolate data collected
during this study to the long-term consequences of recurrent or
frequent hypoglycaemic events in this observational study.
Treatment-induced hypoglycaemia may be limited by improv-
ing patient education and thereby enhancing patient-level man-
agement of anti-diabetic treatment. From data collected in the
current study, there is a need for in-depth patient education
on insulin management as 29% of patients indicated that lack
of diabetes education adversely affected glycaemic control
(see Table 2). It has been suggested that patient empowerment,
through education on diabetes and the prescribed anti-hyper-
glycaemic agents, contributes to overall successful management
of diabetes and the role of the nurse is undisputed.35 The pivotal
role of diabetes nurse educators as part of a multidisciplinary
team to enhance patient education has been reported in the
multinational Diabetes Attitudes Wishes and Needs (DAWN)
study involving various healthcare patients, the level of edu-
cation provided and the rapport between nurses and their
patients.36
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and colleagues investigated patients’ persistence on insulin
treatment after one or more episode of hypoglycaemia.21 The
study demonstrated that 68% of patients who had experienced
hypoglycaemia discontinued insulin treatment in the first 12
months. The incidence of hypoglycaemia was reported as
10.5% in the first six months after initiation of basal insulin
treatment.21
It is important that healthcare professionals identify and
acknowledge the fear of hypoglycaemia. The requisite facility,
through routine outpatient consultation, should be provided
to discuss the fear and develop strategies to assist patients in
overcoming this barrier. A helpful tool designed for this
purpose is the Hypoglycaemia Fear Survey, which, if
implemented in appropriate cases, may prove invaluable in edu-
cating patients and modifying entrenched patient and physician
behaviours.22
Data indicated that 22.4% of patients diagnosed with type 1 dia-
betes and 5.4% of patients diagnosed with T2D experienced at
least one episode of severe hypoglycaemia in the year preced-
ing the study (Table 4). A higher incidence of severe hypoglycae-
mia was reported in patients diagnosed with T2D on treatment
with insulin (14.3%) or the combination of insulin and oral anti-
hyperglycaemic agents (9.6%) than for patients on treatment
with oral anti-hyperglycaemic agents alone (1.4%) (see Table
4). These rates are similar to those reported by Dalal and col-
leagues.21 Another non-interventional study, the Hypoglycaemia
Assessment Tool (HAT), reported that 14.4% of participants diag-
nosed with T1D and 8.9% of participants diagnosed with T2D
reported an episode of severe hypoglycaemia.23 Only patients
on treatment with insulin were included in the HAT study; no
mention was made of the use of oral anti-hyperglycaemic
agents.23
When compared with the results of the HAT study, patients diag-
nosed with T1D in the South African cohort of the IDMPS Wave 7
study seem to experience episodes of hypoglycaemia more fre-
quently. The incidence of severe hypoglycaemia in the T2D
population treated with insulin was reported as > 10% in both
studies. It should be considered that the IDMPS Wave 7 study
recorded episodes of severe hypoglycaemia over a 12-month
period, while the HAT study recorded episodes of severe hypo-
glycaemia over four weeks only. It is not surprising that patients
diagnosed with T1Dmay be at higher risk for severe hypoglycae-
mia than their T2D counterparts.
The cost of hypoglycaemia, and in particular severe hypoglycae-
mia, extends beyond pure economic cost, as hypoglycaemia
affects productivity and quality of life, and remains an obstacle
to reach glycaemic targets. The cost of one event of severe
hypoglycaemia is estimated to range from US$ 1 746 to US$ 3
525.24 Even though differences in healthcare systems do not
allow for direct translation of this cost, it is alarming to note
that hypoglycaemia-related hospitalisation costs increase sub-
stantially when the number of hypoglycaemia events exceeds
six per year.25 Results from the current study (see Table 4) and
the HAT study23 reported hospitalisation due to hypoglycaemia
in both the South African and international cohorts. It must be
considered that therapeutic regimens are often not included
in these health economic reports.
It is well known that some anti-hyperglycaemic treatments,
especially sulfonylureas5 and insulin,6 are associated with
increased risk of hypoglycaemia. In addition, co-morbidities
including renal dysfunction increase the risk of hypoglycae-
mia.26 Considering that insulin is the cornerstone of treatment
for patients diagnosed with T1D,1 the increased incidence of
hypoglycaemia in this population is not completely surprising.
Inappropriate management of insulin, inappropriate dosing of
insulin and inappropriate timing of insulin were mentioned
among the major factors contributing to severe hypoglycaemia
in the present study (see Table 4). To address these factors con-
tributing to severe hypoglycaemia a number of tactics should be
considered, including selecting treatments with low risk of hypo-
glycaemia, a multidisciplinary approach to patient education to
ensure appropriate patient-level management of insulin therapy
and caution in insulin-treated patients with renal failure or in
patients with blunting of awareness of hypoglycaemia.
In order to reduce treatment-related hypoglycaemia, a number
of novel treatments have been developed with lower risk for
hypoglycaemia, such as glucagon-like peptide receptor-1 ago-
nists (GLP-1RAs) and sodium-glucose co-transporter-2 inhibitors.
Clinical study programmes for the GLP-1RAs liraglutide and lixi-
senatide have demonstrated minimal risk for hypoglycaemia in
heterogeneous populations of patients with diabetes.27–29 Fur-
thermore clinical studies on longer acting basal insulins, includ-
ing insulin degludec and insulin glargine U300, have
demonstrated a reduced risk of hypoglycaemia in extensive
phase three clinical trials in comparison with other available
insulin analogues.30–32 Some of these treatments are costly
and the benefit to the patient should be weighed against this
potential increased treatment cost.
A recent study of insulin-naive patients diagnosed with T2D has
demonstrated that patients who experienced hypoglycaemia
during the first three months of initiation of basal insulin
therapy were at higher risk of experiencing recurring hypogly-
caemia.33 As hypoglycaemia may adversely affect the achieve-
ment of glycaemic goals, it is vital to ensure that patients
diagnosed with diabetes and treated with insulin receive appro-
priate education on the treatment as well as the management of
hypoglycaemia.
Recently, reports have alluded to an association between hypo-
glycaemia and adverse cardiovascular events.34 However, the
potential correlation of severe hypoglycaemic events and
macrovascular complications, including acute coronary syn-
dromes, is clearly impossible to gauge given the limited access
to all clinical data. Thus, it is difficult to extrapolate data collected
during this study to the long-term consequences of recurrent or
frequent hypoglycaemic events in this observational study.
Treatment-induced hypoglycaemia may be limited by improv-
ing patient education and thereby enhancing patient-level man-
agement of anti-diabetic treatment. From data collected in the
current study, there is a need for in-depth patient education
on insulin management as 29% of patients indicated that lack
of diabetes education adversely affected glycaemic control
(see Table 2). It has been suggested that patient empowerment,
through education on diabetes and the prescribed anti-hyper-
glycaemic agents, contributes to overall successful management
of diabetes and the role of the nurse is undisputed.35 The pivotal
role of diabetes nurse educators as part of a multidisciplinary
team to enhance patient education has been reported in the
multinational Diabetes Attitudes Wishes and Needs (DAWN)
study involving various healthcare patients, the level of edu-
cation provided and the rapport between nurses and their
patients.36
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A number of caveats must be considered when interpreting data
from the current study. As participants were recruited from the
private healthcare sector only and the racial distribution of the
participants is not reflective of the South African population,
generalisability of the data to the whole South African popu-
lation is limited. Furthermore, due to the study design and
lack of follow-up, the data do not necessarily represent the man-
agement practices of the participating sites. The use of DPP-4
inhibitors, GLP1 receptor agonists and sodium glucose co-trans-
porter-2 inhibitors was restricted in this study due to limited
availability and reimbursement. Due to the small cohort of
T1D patients included in the study, and therefore the limited
information collected on hypoglycaemia in the context of T1D,
additional studies in this population may be warranted.
Conclusion
Management of diabetes is often a balancing act between pre-
venting a state of hyperglycaemia, while avoiding episodes of
hypoglycaemia. However, often episodes of hypoglycaemia
are not reported to healthcare practitioners. Data reported
here from Wave 7 of the International Diabetes Management
Practices Study (IDMPS) indicates that hypoglycaemia is still
prevalent in South African patients diagnosed with diabetes.
With symptomatic or severe hypoglycaemia experienced by
77.6% of patients diagnosed with T1D, and 18% of patients diag-
nosed with T2D over the period of three months, this report con-
firms the need for addressing episodes of hypoglycaemia in the
South African population.
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